Ketamine is legal nationwide with FDA approval as Spravato; ayahuasca contains Schedule I DMT and is only legally accessible in the US through four religious exemptions — most access is via international retreats.
Ayahuasca vs ketamine is a comparison people make when they want a psychedelic or psychedelic-adjacent experience for depression, trauma, or spiritual development and want to understand how the two differ. The differences are wide: one is a traditional ceremonial brew from the Amazon with a complex MAOI mechanism; the other is a dissociative anesthetic from a hospital setting, now widely available as a psychiatric treatment. This guide compares both side by side across every dimension that matters.
Ketamine is the practical option for most people today. It is legal everywhere in the US, has FDA approval in its esketamine form for treatment-resistant depression, and you can start treatment without leaving your home state. Ayahuasca is more intense, more traditional, and more legally restricted. It is a better fit for people who specifically want a long, immersive ceremonial experience and are willing to travel abroad and do a full medication washout. For clinical depression, ketamine wins on access and evidence. For deep spiritual or trauma work in a ceremonial context, ayahuasca is the tradition with the longest history — but it requires far more preparation.
| Factor | Ayahuasca | Ketamine |
|---|---|---|
| Legal status (US) | Schedule I (contains DMT). Legal only via four DEA-recognized religious exemptions (UDV, Santo Daime, and two smaller churches). Retreats abroad are the main access route. | Schedule III. Legal nationwide for clinical use. Spravato (esketamine) is FDA-approved for treatment-resistant depression. |
| How it works | B. caapi vine (harmaline/harmine — MAOI) + P. viridis (DMT — 5-HT2A agonist). The MAOI prevents gut breakdown of DMT, enabling the oral psychedelic effect. | NMDA glutamate receptor antagonist (a dissociative). Works on a completely different neurotransmitter system from classic psychedelics. |
| Session duration | 4–8 hours of active effects. Ceremonies often start at night and run through dawn. | 40–60 minutes of active dissociative effects. Most protocols use 6+ sessions. |
| FDA / regulatory status | No FDA approval. Not in Phase 3 clinical trials (niche trial activity only). | Esketamine (Spravato) is FDA-approved for treatment-resistant depression (2019, expanded January 2025 to monotherapy). IV ketamine is off-label but widely used. |
| Evidence strength (depression) | Phase 2 open-label trials show significant antidepressant effects. No large randomized Phase 3 trial yet. | Strong short-term antidepressant data from multiple RCTs. Spravato had pivotal FDA registration trials. |
| Critical safety issue | MAOI drug interactions — SSRIs, SNRIs, lithium, stimulants, certain foods. Serotonin syndrome risk. Full washout required. | Blood pressure elevation, dissociation, bladder toxicity (chronic high-frequency use), abuse liability. |
| Purging / physical effects | Nausea and vomiting are common and considered part of the ceremony by many traditions. Diarrhea also occurs. | No nausea at therapeutic doses under most protocols. IV can cause mild nausea in some patients. |
| Where to access it legally | International retreats in Peru, Brazil, Costa Rica, the Netherlands, and elsewhere. The four US religious organizations. | Ketamine clinics and telehealth nationwide. Spravato at REMS-certified offices. Insurance often covers Spravato. |
| Typical cost | $1,500–$5,000 for a multi-night international retreat (not including travel and accommodation). | $150–$400/month telehealth; $400–$800/IV session in clinic. Spravato often covered by insurance. |
Ayahuasca is a brew prepared by combining two plants: Banisteriopsis caapi (which contains beta-carboline MAOIs — harmaline, harmine, and tetrahydroharmine) and Psychotria viridis (which contains DMT). The MAOI compounds in the vine inhibit monoamine oxidase enzymes in the gut and liver, which would otherwise break down DMT before it reaches the brain. Without the vine, oral DMT is inactive. Together, they produce a 4–8 hour psychedelic experience.
At the receptor level, DMT acts primarily as a 5-HT2A serotonin receptor agonist — the same mechanism as psilocybin and LSD. This places ayahuasca firmly in the "classic psychedelic" category in terms of how the visionary experience works. But the MAOI component adds another dimension: by blocking MAO enzymes, it also prevents breakdown of serotonin and dopamine, which contributes to mood effects and also creates the dangerous interaction profile with serotonergic medications. Read our full ayahuasca guide for a complete breakdown of the pharmacology.
Ketamine works on a completely different system. It blocks the NMDA glutamate receptor, triggering a rapid burst of new synaptic connections that many researchers link to its antidepressant effect. It is a dissociative anesthetic, not a classic psychedelic. At therapeutic doses it creates a floating, detached experience. Most people remain aware of their surroundings. Sessions end in under an hour. Our full ketamine guide covers the mechanism in depth.
Ayahuasca has meaningful Phase 2 evidence for depression. A 2019 randomized controlled trial in Brazil by Palhano-Fontes et al., published in Psychological Medicine, found rapid antidepressant effects after a single ayahuasca session versus placebo (inactive herbal tea).1 Effect sizes were large on the MADRS scale at day 7. The trial was small (n=29) and used ayahuasca under controlled clinical conditions — not the same as an international retreat. Open-label observational studies from the same group and others consistently show antidepressant effects. But no large Phase 3 trial exists, and there is no FDA Breakthrough Therapy designation for ayahuasca.
Ketamine has the longer and deeper evidence track record. Multiple randomized controlled trials show robust short-term antidepressant effects, with response often within hours of a single dose.2 Spravato (esketamine) went through full FDA registration trials and was approved in 2019. In January 2025, the FDA expanded the approval to allow Spravato as a monotherapy for treatment-resistant depression, making it the only standalone antidepressant in that category.3 The main weakness is durability: ketamine's effects on depression often fade without repeat dosing.
Ketamine is Schedule III — doctors can prescribe it in any US state. Spravato is available at REMS-certified clinician offices and is often covered by insurance for TRD. Telehealth providers can prescribe compounded ketamine lozenges to most states. Use the ketamine provider finder to see options near you.
Ayahuasca contains DMT, which is Schedule I in the US. It is not available by prescription and no state has created a regulated access program. The four recognized religious exemptions (UDV, Santo Daime, and two smaller organizations) allow those specific groups to use ayahuasca sacramentally — but joining these groups for access is not practical for most people. The typical legal path is an international retreat in Peru, Brazil, Costa Rica, or the Netherlands, where local legal frameworks differ. Read our ayahuasca retreats roundup for vetted options.
The harmala alkaloids in ayahuasca inhibit MAO enzymes. This means any medication that raises serotonin levels — SSRIs, SNRIs, most antidepressants, some pain medications — can trigger serotonin syndrome in combination with ayahuasca. Serotonin syndrome ranges from mild (tremor, agitation, sweating) to life-threatening (hyperthermia, muscle rigidity, death). Washout periods for SSRIs are typically two to four weeks (five weeks for fluoxetine due to its long half-life) before an ayahuasca session. Lithium is also a hard contraindication — it lowers the seizure threshold in a way that combines dangerously with DMT. See our detailed medication safety guide before planning any psychedelic session.
Beyond medications, ayahuasca ceremonies often involve nausea and purging, which are expected and in some traditions considered part of the healing. The long duration (4–8 hours) means difficult emotional material may surface and must be worked through without an easy exit.
Ketamine's main safety considerations in clinical use are blood pressure elevation during sessions, acute dissociation, and — with chronic high-frequency use — bladder toxicity. At-home telehealth ketamine is the most legally uncertain model: DEA telehealth flexibilities that enabled it are under ongoing policy review. The quality of screening and follow-up varies widely across providers. Spravato in a REMS-certified office has the most regulatory oversight of any ketamine delivery method.
Ketamine is the cheaper and more accessible option by a wide margin. The depression treatment path tool walks through the cost comparison for Spravato, IV ketamine, and at-home telehealth side by side.
Choose ketamine if you have treatment-resistant depression, need a legally accessible and evidence-backed option, want insurance coverage to be possible (Spravato), or need results quickly. Ketamine is the only treatment here you can access in all 50 states today without travel.
Choose ayahuasca if you specifically want the full traditional ceremonial experience, are prepared for the MAOI medication washout, can manage the cost of travel to an international retreat, and want a long, immersive experience rather than a short clinical one. Ayahuasca's evidence for depression is real but earlier-stage. The ceremonial context and the duration of the experience are distinct in ways that some people find more meaningful than a clinical session.
Not sure where to start? Take our which psychedelic quiz for a personalized comparison of your options based on your goals and legal situation.
Ketamine has stronger and more extensive clinical evidence for depression. Spravato (esketamine) is FDA-approved specifically for treatment-resistant depression and can be prescribed nationwide. Ayahuasca has compelling Phase 2 randomized trial data showing rapid antidepressant effects, but no Phase 3 trial and no FDA approval. Ketamine also wins on access — it is legal in all 50 US states while ayahuasca requires international travel or membership in one of four recognized religious organizations.
No — not without a full washout, and only under medical supervision. Ayahuasca contains MAOI compounds (harmaline, harmine) that prevent the breakdown of serotonin. Combining ayahuasca with SSRIs, SNRIs, or other serotonergic medications can cause serotonin syndrome, which can be life-threatening. SSRIs require a two to four week washout before an ayahuasca session; fluoxetine requires five weeks due to its long half-life. Lithium is also a hard contraindication. Never make this switch without a prescriber involved in the planning.
The experiences are very different. Ayahuasca lasts 4 to 8 hours, is highly visual, emotionally intense, and traditionally conducted in a ceremonial setting overnight. Nausea and purging are common. Ketamine lasts 40 to 60 minutes, produces a floating dissociative state, and is administered in a clinical setting. Ayahuasca is more immersive and spiritually oriented; ketamine is more contained and medical in character.
Ayahuasca contains DMT, which is Schedule I in the US, making it federally illegal. Legal use in the US is limited to four religious organizations recognized by the federal government under the Religious Freedom Restoration Act: the UDV (União do Vegetal), Santo Daime, and two smaller organizations. For most people, legal access to ayahuasca means traveling to Peru, Brazil, Costa Rica, the Netherlands, or another country where the legal framework differs.
Get psychedelic research & policy updates
New trials, FDA decisions, and legal changes for psychedelic — delivered when they happen.
Suggest a tool, topic, or improvement that would make this site more useful.